Nivolumab Reactions 1680, p255 - 2 Dec 2017 Intracorneal pustular drug eruption, actinic keratosis and porokeratosis: case report An elderly man [age at the time of reaction onset not clearly stated] developed intracorneal pustular drug eruption, actinic keratosis and porokeratosis during treatment with nivolumab [dosage not stated]. The man was diagnosed melanoma of the right calf in September 2014 at the age of 79 years. In May 2016, his melanoma progressed and metastasised to his brain. As a result, in May 2016, he started receiving treatment with nivolumab infusions every two weeks. Eight weeks later, after four nivolumab cycles, he developed non-tender, erythematous scaly plaques and pustules on the legs, forehead and arms. The histology showed intracorneal pustules with dermal neutrophils and eosinophils. Consequently, a diagnosis of intracorneal pustular drug eruption, with an incidental diagnosis of actinic keratosis and porokeratosis was made. The man was treated with betamethasone-valerate and urea cream. Following the treatment, his intracorneal pustular drug eruption resolved. His nivolumab therapy was continued and metastatic melanoma remained stable. Author comment: "We present the first case of intracorneal pustular drug eruption in association with nivolumab, a new cutaneous adverse event associated with anti-[programmed cell death-1]." Zhao CY, et al. Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti- programmed cell death-1 in neutrophils. Melanoma Research 27: 641-644, No. 6, Dec 2017. Available from: URL: - Australia 803284591 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial